Archives
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2018-07
-
Staurosporine: Translational Leverage in Kinase Inhibition
2026-06-12
This thought-leadership article examines Staurosporine’s pivotal role as a broad-spectrum serine/threonine protein kinase inhibitor in translational cancer research. Drawing from mechanistic insights, advanced protocols, and quantitative imaging breakthroughs, we guide researchers in harnessing Staurosporine for high-impact studies on apoptosis, angiogenesis, and kinase pathway dissection. Strategic recommendations and protocol parameters are provided for maximizing reproducibility and translational value.
-
LncRNA FAISL Blocks Calpain 2-FAK Cleavage to Drive TNBC Pro
2026-06-12
This study uncovers how the long non-coding RNA FAISL promotes triple negative breast cancer (TNBC) progression by directly inhibiting calpain 2-mediated proteolysis of FAK, stabilizing FAK protein and enhancing malignant cell behavior. These findings highlight a novel regulatory axis in TNBC and suggest new potential intervention points for targeting focal adhesion signaling.
-
I-BET-762: BET Inhibitor Workflows for Ferroptosis & Inflamm
2026-06-11
I-BET-762 enables precision interrogation of BET protein function in both cancer biology and inflammation models, showing synergistic effects with ferroptosis inducers. This article translates recent mechanistic insights and practical benchmarks into actionable workflows and troubleshooting strategies for advanced research applications.
-
Cy3 NHS Ester (Non-Sulfonated): Technical Guidance and QC
2026-06-11
Cy3 NHS ester (non-sulfonated) enables robust, covalent fluorescent labeling of proteins, peptides, and oligonucleotides through primary amine groups in workflows compatible with organic co-solvents. It is not suitable for applications requiring strictly aqueous conditions or for labeling highly co-solvent-sensitive proteins. This article provides actionable guidance to optimize labeling efficiency and minimize common pitfalls.
-
Protein A/G Magnetic Beads: Technical Guide and Best Practic
2026-06-10
Protein A/G Magnetic Beads (SKU K1305) streamline antibody purification and protein-protein interaction studies, providing high specificity and minimized background in immunoprecipitation workflows. These recombinant Protein A and Protein G beads are not suitable for diagnostic or therapeutic applications, nor for targets outside IgG Fc regions.
-
7-AAD Cell Viability Assays: Precision Tools for Translation
2026-06-10
Explore how advanced 7-amino actinomycin D-based viability assays are transforming cellular analysis in translational immunotherapy. This thought-leadership article bridges mechanistic insights from recent CD38 CAR-T structural studies with strategic assay guidance, spotlighting the APExBIO 7-AAD Cell Viability Assay Kit and its role in multiplexed, high-fidelity research.
-
Ferrostatin-1 (Fer-1): Precision Inhibition of Ferroptosis i
2026-06-09
Ferrostatin-1 (Fer-1) empowers researchers to precisely dissect and inhibit ferroptosis, supporting advanced workflows in cancer and neurodegeneration studies. This guide translates bench protocols, workflow enhancements, and troubleshooting tips into actionable insights for maximizing the power of Fer-1 in complex oxidative cell death models.
-
EZ Cap Cy5 Firefly Luciferase mRNA: Dual-Mode Reporter Advan
2026-06-09
EZ Cap Cy5 Firefly Luciferase mRNA (5-moUTP) offers robust dual-modality detection for mRNA delivery and transfection studies. This Cap1-capped, 5-moUTP-modified, Cy5-labeled mRNA enables high translation efficiency and reduced innate immune activation in mammalian systems.
-
Epigenetic Regulation of Vasoconstriction via TPM3 Khib Modu
2026-06-08
This study reveals that HDAC3-driven de-2-hydroxyisobutyrylation of tropomyosin 3 (TPM3) at Lys141 is a pivotal mechanism controlling vascular smooth muscle contractility and abnormal vasoconstriction. By connecting posttranslational modification dynamics to hypertensive vascular dysfunction, the findings highlight new therapeutic avenues and technical considerations for protein-protein interaction analysis in cardiovascular research.
-
TEAD Transcription Factors: Prognostic Role and Ferroptosis
2026-06-08
This study identifies the TEAD family, especially TEAD2 and TEAD4, as upregulated and prognostically significant in hepatocellular carcinoma (HCC). Integrative bioinformatics and experimental analysis reveal that downregulating TEAD2 promotes ferroptosis in HCC cells, highlighting TEADs as potential diagnostic and therapeutic targets.
-
a-MSH, amide: Protocols and Innovation in Pigmentation Resea
2026-06-07
a-MSH, amide empowers precision in both pigmentation regulation and anti-inflammatory peptide research, offering reproducible results and workflow versatility. This article details stepwise experimental best practices, troubleshooting strategies, and bridges new protocol insights from recent studies to practical laboratory contexts.
-
Mechanisms of Gepotidacin and Implications for DNA Gyrase In
2026-06-06
This article analyzes the mechanistic and structural insights gained from the study of gepotidacin’s action on Staphylococcus aureus gyrase. The findings reveal how gepotidacin’s unique mode of inhibiting DNA gyrase differs from fluoroquinolones, providing context for antibiotic resistance research and informing future experimental workflows involving gyrase inhibitors.
-
VX-765: Precision Caspase-1 Inhibition for Inflammation Rese
2026-06-05
VX-765 offers potent, selective inhibition of caspase-1, empowering researchers to dissect pyroptosis and cytokine release with confidence in both cellular and in vivo models. This guide details optimized workflows, advanced troubleshooting, and actionable protocol parameters to maximize data quality when leveraging VX-765 for inflammation and immune cell death studies.
-
FPR2/ALX Stimulation Restricts CNS Autoimmune Astrocytopathy
2026-06-05
The reference study demonstrates that stimulating FPR2/ALX with the agonist Quin-C1 modulates microglia and NK cell activity to attenuate neuroinflammation and demyelination in a mouse model of autoimmune astrocytopathy. These findings provide mechanistic insight into the SYK-AKT pathway and highlight a novel immunomodulatory strategy for CNS autoimmune diseases such as NMOSD.
-
PF-562271 HCl in Combination Therapies: Redefining FAK/Pyk2
2026-06-04
Explore how PF-562271 HCl, a potent FAK/Pyk2 inhibitor, is reshaping cancer research by enabling advanced combination therapies and immune modulation strategies. Discover unique mechanistic insights and protocol guidance that go beyond standard applications.